WALTHAM, Mass., Dec. 13 /PRNewswire-FirstCall/ -- Repligen Corporation
(Nasdaq: RGEN) announced today that Dr. Earl Webb Henry, M.D. has been
elected to its Board of Directors. Dr. Henry is a highly experienced
executive with worldwide clinical and regulatory expertise in the
development of therapeutics for disorders affecting the Central Nervous
System.
"We are very pleased to welcome an executive with Earl's industry
knowledge and drug development expertise to our Board," stated Walter C.
Herlihy, President and Chief Executive Officer of Repligen Corporation.
"Earl's strategic guidance and relationships within the medical community
will be an invaluable asset to the Company as we develop and expand our
emerging CNS pipeline."
Dr. Henry has held numerous executive level positions including Senior
Vice President and Head, Worldwide Clinical Research and Regulatory Affairs
for Cephalon, Inc., Vice President, Clinical Research for Guilford
Pharmaceuticals Inc., Global Head of Central Nervous System Therapeutic
Area for Sandoz Research Institute and Senior Associate Director of
Clinical Research for Pfizer. Dr. Henry has participated in the development
and approval of numerous neurologic and psychiatric drugs. Dr. Henry earned
his medical degree from the University of Chicago and completed his
residence and fellowship at Harvard Medical School in neurology and
neuropathology. Dr. Henry is currently Senior Vice President, Medical
Affairs for inVentiv Clinical Solutions, a premier provider of clinical
outsourcing solutions.
About Repligen Corporation
Repligen Corporation is a biopharmaceutical company focused on the
development of novel therapeutics for diseases that affect the central
nervous system. In addition, we are the world's leading supplier of
recombinant Protein A, the sales of which partially fund the advancement of
our development pipeline while supporting our financial stability.
Repligen's corporate headquarters are located at 41 Seyon Street, Building
#1, Suite 100, Waltham, MA 02453. Additional information may be requested
from http://www.repligen.com.
This press release contains forward-looking statements which are made
pursuant to the safe harbor provisions of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. The forward-looking statements in this release do not
constitute guarantees of future performance. Investors are cautioned that
statements in this press release which are not strictly historical
statements, including, without limitation, statements regarding current or
future financial performance and position, management's strategy, plans and
objectives for future operations, plans and objectives for product
development, plans and objectives for present and future clinical trials
and results of such trials, plans and objectives for regulatory approval,
litigation, intellectual property, product development, manufacturing plans
and performance such as the anticipated growth in the monoclonal antibody
market and our other target markets and projected growth in product sales,
constitute forward-looking statements. Such forward-looking statements are
subject to a number of risks and uncertainties that could cause actual
results to differ materially from those anticipated, including, without
limitation, risks associated with: the success of current and future
collaborative relationships, the market acceptance of our products, our
ability to compete with larger, better financed pharmaceutical and
biotechnology companies, new approaches to the treatment of our targeted
diseases, our expectation of incurring continued losses, our uncertainty of
product revenues and profits, our ability to generate future revenues, our
ability to raise additional capital to continue our drug development
programs, the success of our clinical trials, our ability to develop and
commercialize products, our ability to obtain required regulatory
approvals, our compliance with all Food and Drug Administration
regulations, our ability to obtain, maintain and protect intellectual
property rights for our products, the risk of litigation regarding our
intellectual property rights, our limited sales and manufacturing
capabilities, our dependence on third-party manufacturers and value added
resellers, our ability to hire and retain skilled personnel, our volatile
stock price, and other risks detailed in Repligen's filings with the
Securities and Exchange Commission. Repligen assumes no obligation to
update any forward-looking information contained in this press release or
with respect to the announcements described herein.
SOURCE Repligen Corporation
 back to top
Related links:
http://www.repligen.com/
CONTACT:
Walter C. Herlihy, Ph.D., President and Chief
Executive Officer, +1-781-250-0111, ext. 2000, or Laura L.
Whitehouse, Vice President, Market Development, +1-781-250-0111,
ext. 2306, both of Repligen Corporation
|
